Medical technology company MiniMed announced on Monday that it will report its 2027 fiscal first quarter financial results after the U.S. market closes on Tuesday, July 28, 2026. Following the release, the company's management will host a conference call to discuss the results and answer questions from analysts.
MiniMed is a medical device firm focused on the diabetes management field. Its core products include insulin pumps, continuous glucose monitoring systems, and smart insulin delivery algorithms, designed to provide more precise and convenient blood glucose control solutions for diabetic patients. The company went public on the Nasdaq in 2023.
Market expectations are for MiniMed's first-quarter revenue to be in the range of $140 million to $150 million, representing a year-over-year increase of approximately 18% to 20%. Analysts are particularly focused on the market acceptance of its new-generation hybrid closed-loop insulin delivery system, changes in U.S. Medicare coverage for new diabetes devices, and the progress of its international market expansion.
In its 2026 fiscal fourth-quarter earnings report, MiniMed previously announced that its next-generation automated insulin delivery system had received approval from the U.S. Food and Drug Administration and had begun a limited launch in the U.S. market. Investors are hoping to learn about the initial user adoption rate of this product and the progress of insurance coverage negotiations in this quarter's report.
Recently, MiniMed has also expanded its sales teams in the European and Japanese markets and launched a simplified version of its insulin management device for type 2 diabetes. This move aims to extend its business scope from the traditional type 1 diabetes market to the broader type 2 diabetes population. Analysts will be watching whether the initial performance of these new markets and products meets expectations.
MiniMed is scheduled to hold its earnings conference call at 5:00 p.m. Eastern Time on July 28. Investors can listen to the live webcast via the investor relations section of the company's website.